Natural killer cell therapy with temozolomide for melanoma that has spread to the brain
Tests donor immune cells and temozolomide in adults with melanoma spread to the brain.
Key facts
- Who runs it
- Kari Kendra
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 24 people, planned
- Started
- 1 Mar 2023
- Expected to end
- 15 Apr 2027
- Type of study
- Interventional
- Treatments tested
- Natural Killer Cell Therapy
- Temozolomide
- Record updated
- 11 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV melanoma that has spread to the brain. It tests natural killer (NK) cell infusions together with temozolomide.
- Age
- Over 18 years old
- Sex
- Everyone can join
- Disease stage
- Melanoma that is confirmed under the microscope as stage IV. At least 1 brain metastasis confirmed on scans, with at least one measurable brain lesion of 10 mm or more and clear signs that it is growing. No indication for stereotactic radiotherapy.
- Earlier treatment
- At least 4 weeks since any cancer treatment (chemotherapy, signal transduction inhibitors, immunotherapy or radiation).
Main reasons for not taking part
- Planned or ongoing systemic treatment or radiation therapy
- Leptomeningeal metastases seen on MRI
- Active infection, or current active liver or kidney disease
- Pregnant, likely to become pregnant or breastfeeding
- Other investigational drugs or another treatment trial within the last 30 days
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Histologically confirmed melanoma with stage IV disease
- Radiologically confirmed brain metastasis (n >= 1) with at least one measurable central nervous system (CNS) lesion >= 10 mm on T1-weighted gadolinium enhanced magnetic resonance imaging (MRI) and unequivocal evidence of progression
- No indication for stereotactic radiotherapy
- At least 4 weeks from any anticancer treatment (cytotoxic chemotherapy, signal transduction inhibitors, immunotherapy or radiation)
- Absolute neutrophil count (ANC) 1 x 10\^9/L
- Platelets > 100,000/L
- Hemoglobin (Hgb) >= 10 g/dL
- Creatinine =< 1.5 x upper limit of normal (ULN)
- Albumin >= 2.5 g/dL
- Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN if documented liver metastases or < 3 X ULN without liver metastasis
- > 18 years old (y/o)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Females of reproductive age must agree to the use of an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women. Males able to father a child must practice adequate methods of contraception or completely abstain from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment
- Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment
- Patient information and written informed consent form signed
Who cannot take part
- Planned or concurrent systemic treatment or radiation therapy
- If requiring corticosteroids for cerebral edema, patients must be on a stable dose. Lowest dose of steroids needed to control CNS edema is recommended. Doses above 4 mg daily need to be cleared by principal investigator (PI) of the study
- Patients with non-melanoma malignancies are excluded unless a complete remission has been achieved at least 3 years prior to study entry and no additional therapy is required or anticipated during the study period (exceptions include: non-melanoma skin cancers, in situ bladder cancer, in situ gastric cancer, in situ colon cancers, in situ cervical cancers/dysplasia, or in situ breast carcinoma)
- Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as:; Active infection; Current active hepatic or renal disease; Pregnant women, women who are likely to become pregnant or are breastfeeding; Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological, or geographical conditions potentially hampering ability to consent, compliance with the study protocol, and follow-up schedule; those conditions should be discussed with the patient before remigration in the trial; Patients who received any other investigational drugs within the 30 days prior to screening visit; Leptomeningeal metastases diagnosed by MRI; Inclusion in another therapeutic protocol within 30 days; If steroids are necessary to control symptoms related to CNS metastases, patients should be on the lowest dose of steroids necessary to control symptoms
- Known contra-indication to MRI
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Kari L. Kendra, MDTaking people
About the trial
What the trial wants to find out
This phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV melanoma that has spread to the brain (metastatic to the brain). NK cells are immune cells that contribute to anti-tumor immunity by recognizing and destroying transformed or stressed cells. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in the body. Giving UD TGFbetai NK cell and temozolomide may work better in treating patients with stage IV melanoma.
The group in the trial
- Treatment (UD TGFbetai NK cells, temozolomide)Treatment being tested
Patients receive UD TGFbetai NK cells IV over 30 minutes on day 1 and temozolomide PO daily on days 1-5. Treatment with UD TGFbetai NK cells repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Cycles of temozolomide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment: Natural Killer Cell Therapy and Temozolomide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain
- Plain-language title
- Natural killer cell therapy with temozolomide for melanoma that has spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 June 2026